Based on the Xenon Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for Xenon Pharmaceuticals Inc is USD 54.60 over the next 12 months. Xenon Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Xenon Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Xenon Pharmaceuticals Inc’s stock price was USD 41.75. Xenon Pharmaceuticals Inc’s stock price has changed by -8.72% over the past week, -0.02% over the past month and +40.34% over the last year.
No recent analyst target price found for Xenon Pharmaceuticals Inc
No recent average analyst rating found for Xenon Pharmaceuticals Inc
Company Overview Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Read Less
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, w...Read More
Frequently Asked Questions About Xenon Pharmaceuticals Inc (XENE) Stock
Based on ratings from 6 analysts Xenon Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on XENE's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for XENE is USD 54.60 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 46.
Unfortunately we do not have enough data on XENE's stock to indicate if its overvalued.
The last closing price of XENE's stock was USD 41.75.
The most recent market capitalization for XENE is USD 3.17B.
Based on targets from 6 analysts, the average taret price for XENE is projected at USD 54.60 over the next 12 months.
This means that XENE's stock price may go up by +30.78% over the next 12 months.
We can't find any ETFs which contains Xenon Pharmaceuticals Inc's stock.
As per our most recent records Xenon Pharmaceuticals Inc has 251 Employees.
Xenon Pharmaceuticals Inc's registered address is 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8.
You can get more information about it from Xenon Pharmaceuticals Inc's website at https://www.xenon-pharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Xenon Pharmaceuticals Inc (XENE) Stock
Based on ratings from 6 analysts Xenon Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on XENE's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for XENE is USD 54.60 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 46.
Unfortunately we do not have enough data on XENE's stock to indicate if its overvalued.
The last closing price of XENE's stock was USD 41.75.
The most recent market capitalization for XENE is USD 3.17B.
Based on targets from 6 analysts, the average taret price for XENE is projected at USD 54.60 over the next 12 months.
This means that XENE's stock price may go up by +30.78% over the next 12 months.
We can't find any ETFs which contains Xenon Pharmaceuticals Inc's stock.
As per our most recent records Xenon Pharmaceuticals Inc has 251 Employees.
Xenon Pharmaceuticals Inc's registered address is 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8.
You can get more information about it from Xenon Pharmaceuticals Inc's website at https://www.xenon-pharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XENE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
